KRT19 and benign prostatic hyperplasia: μ was found significantly lower in non-muscle-invasive bladder cancer than muscle-invasive bladder cancer and in the high- than low-grade bladder cancer [18], while no differences between benign prostatic hyperplasia and prostate cancer, or between Cytokeratin 19-positive and Cytokeratin 19-negative HCCs, were observed [23, 26].